Guoying Cao

Jiangsu University — China

Medicine · Health Sciences

19h-index1.4kcitations75works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotics Pharmacokinetics and Efficacy(35), Antibiotic Resistance in Bacteria(22), Pneumonia and Respiratory Infections(19), Antimicrobial Resistance in Staphylococcus(10), Biosimilars and Bioanalytical Methods(4)

Publications75 total

[Application of vancomycin antibiotic bone cement combined with induced membrane skin grafting in the treatment of diabetic foot ulcer].
PubMed·2025
Association between the urine tobacco metabolite levels and physical health in Chinese primary school students with secondhand smoke exposure
Frontiers in Public Health·2025· 1 citedOpen Access
Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial
Vaccines·2025Open Access
Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy chinese participants: A first-in-human phase I clinical study
International Journal of Antimicrobial Agents·2024· 4 cited
Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia
Frontiers in Pharmacology·2024· 1 citedOpen Access
A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
The Journal of Clinical Pharmacology·2024· 4 citedOpen Access
First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects
Antimicrobial Agents and Chemotherapy·2023· 8 citedOpen Access
2157. Phase 1 Study in Healthy Chinese Subjects of Novel Prodrug, MRX-4
Open Forum Infectious Diseases·2023Open Access
A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
Antimicrobial Agents and Chemotherapy·2023· 7 citedOpen Access
Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
Antibiotics·2023· 3 citedOpen Access
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
Expert Opinion on Investigational Drugs·2023· 5 cited
Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
Frontiers in Pharmacology·2023· 4 citedOpen Access
Population pharmacokinetics and exposure-safety of lipophilic conjugates prodrug DP-VPA in healthy Chinese subjects for dose regime exploring
European Journal of Pharmaceutics and Biopharmaceutics·2023· 3 cited
Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
Frontiers in Pharmacology·2023· 3 citedOpen Access
Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
Advances in Therapy·2023· 5 citedOpen Access
Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis
International Journal of Antimicrobial Agents·2023· 2 cited
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
Figshare·2023Open Access
Pharmacokinetic evaluation and relative bioavailability pilot study of fidaxomicin in healthy Chinese subjects: An open, randomized, single-dose, cross-over study
International Journal of Clinical Pharmacology and Therapeutics·2022
Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
Antibiotics·2022Open Access
Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
Antibiotics·2022· 12 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Jing Zhang(30), Jicheng Yu(28), Xiaojie Wu(28), Yuancheng Chen(23), Jufang Wu(20), Beining Guo(19), Yingyuan Zhang(16), Yaoguo Shi(13), Hailan Wu(8), Xin Hu(7), Yaxin Fan(7), Jingjing Wang(7), Yi Li(7), Jian Li(5), Aixin Shi(5), Wei Xue(5), Haijing Yang(5), Jing Zhang(5), Bei Yan(4), Kexin Li(4)